Psychopharmacologic treatment of borderline personality disorder
| Autor: | Luis H. Ripoll |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Aggression Atypical antipsychotic Interpersonal communication Dissociative Impulsivity medicine.disease law.invention Randomized controlled trial law mental disorders medicine Psychopharmacology medicine.symptom Psychology Psychiatry Borderline personality disorder Clinical psychology |
| Zdroj: | Dialogues in Clinical Neuroscience. 15:213-224 |
| ISSN: | 1958-5969 |
| DOI: | 10.31887/dcns.2013.15.2/lripoll |
| Popis: | The best available evidence for psychopharmacologic treatment of borderline personality disorder (BPD) is outlined here. BPD is defined by disturbances in identity and interpersonal functioning, and patients report potential medication treatment targets such as impulsivity, aggression, transient psychotic and dissociative symptoms, and refractory affective instability Few randomized controlled trials of psychopharmacological treatments for BPD have been published recently, although multiple reviews have converged on the effectiveness of specific anticonvulsants, atypical antipsychotic agents, and omega-3 fatty acid supplementation. Stronger evidence exists for medication providing significant improvements in impulsive aggression than in affective or other interpersonal symptoms. Future research strategies will focus on the potential role of neuropeptide agents and medications with greater specificity for 2A serotonin receptors, as well as optimizing concomitant implementation of evidence-based psychotherapy and psychopharmacology, in order to improve BPD patients' overall functioning. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|